CS
ENZN

Credit Suisse’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Credit Suisse’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-25,604
Closed -$17K – 4465
2015
Q4 		$17K Sell
25,604
-288
-1% -$228 ﹤0.01% 4178
2015
Q3 		$25K Buy
25,892
+291
+1% +$358 ﹤0.01% 4215
2015
Q2 		$31K Sell
25,601
-54,338
-68% -$69.2K ﹤0.01% 4491
2015
Q1 		$85K Sell
79,939
-15,900
-17% -$16.4K ﹤0.01% 4244
2014
Q4 		$104K Sell
95,839
-5,104
-5% -$5.36K ﹤0.01% 4427
2014
Q3 		$109K Buy
100,943
+22,913
+29% +$28.3K ﹤0.01% 4286
2014
Q2 		$81K Buy
78,030
+37,603
+93% +$35.8K ﹤0.01% 4566
2014
Q1 		$42K Sell
40,427
-6,740
-14% -$6.96K ﹤0.01% 4588
2013
Q4 		$55K Buy
47,167
+11,624
+33% +$17.9K ﹤0.01% 4524
2013
Q3 		$60K Buy
35,543
+19,536
+122% +$36.1K ﹤0.01% 4143
2013
Q2 		$32K Buy
+16,007
New +$46.9K ﹤0.01% 4126

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Credit Suisse's ENZN Position: Q1 2016 in Review

Credit Suisse sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q1 2016, closing a stake of 25,604 shares — an estimated $17K sold.

Credit Suisse first reported a position in ENZN in Q2 2013 and held it in 11 quarters. The position peaked at $109K in Q3 2014. 40 funds tracked by Wall St. Rank hold ENZN as of Q1 2016.

  • Credit Suisse reported no remaining ENZON PHARMACEUTICALS INC position as of Q1 2016 after selling out during the quarter.
  • Credit Suisse sold 25,604 ENZON PHARMACEUTICALS INC shares in Q1 2016, an estimated $17K.
  • Credit Suisse first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 11 quarters.
  • Credit Suisse's ENZON PHARMACEUTICALS INC position peaked at $109K in Q3 2014.
  • 40 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q1 2016.

Based on Credit Suisse's 13F filing for Q1 2016, filed 16 May 2016.